首页
法规动态2026年9月8日•1 分钟阅读

FDA Approves ANDA077766 for Simvastatin Generic Tablets

作者:PharmaCountry 团队

The FDA granted approval for Chartwell Rx's ANDA077766, covering five discontinued Simvastatin tablet strengths and subsequent labeling updates.

The U.S. Food and Drug Administration has approved Abbreviated New Drug Application (ANDA) number 077766 submitted by Chartwell Rx. The application encompasses five oral tablet products of the generic drug Simvastatin, available in strengths of 5 mg, 10 mg, 20 mg, 40 mg, and 80 mg. All five products are recorded with a marketing status of "Discontinued" and are not designated as reference drugs or reference standards. Each product is identified by a unique product number ranging from 001 to 005. The original submission (submission #1, type ORIG) received approval on 20 December 2006. Subsequent supplemental submissions (#2 on 10 July 2007, #3 on 19 October 2012, #4 on 28 December 2015, and #5 on 28 December 2015) were approved for labeling changes, each with a standard review priority. The FDA posting includes an additional document linked at http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm203669.htm, dated 26 May 2011.

由 PharmaCountry 团队整理 · 来源: FDA.gov

更多文章

查看所有资讯